Residual platelet reactivity after pre-treatment with ticagrelor prior to primary percutaneous coronary intervention is associated with suboptimal myocardial reperfusion

Abstract

Background:

The evidence of a clinical benefit of P2Y12 inhibitor pre-treatment in primary percutaneous coronary intervention (PCI) and the relation between the level of platelet inhibition and myocardial reperfusion with newer potent P2Y12 inhibitors remain unclear. We aimed to assess the relationship between platelet reactivity at the time of primary PCI after pre-treatment with aspirin and ticagrelor and the post-PCI myocardial blush grade (MBG).

Methods:

We prospectively included 61 patients. Platelet reaction units for ticagrelor (PRU) and aspirin reaction units (ARU) were measured using the point-of-care test VerifyNow before PCI. The high on-ticagrelor (PRU >208) and on-aspirin (ARU ⩾ 550) platelet reactivity (HPR and HaPR) were assessed. Patients were divided into two groups according to MBG 3 or <3.

Results:

MBG 3 was identified in 28 (46%) patients. Mean PRU was lower in such patients as compared with those with MBG <3 (155.82 ± 90.91 vs. 227.42 ± 65.18; p=0.001) while mean ARU was similar between groups. HPR and HaPR were observed in 30 (49.2%) and 11 patients (18%), respectively. HPR but not HaPR was more frequent in the group with impaired MBG (66.7 vs. 28.6%; p=0.003 and 21.2 vs. 14.3%; p=0.48 respectively).

Conclusion:

Our study shows that higher PRU and the subsequent HPR at the time of primary PCI, after pretreatment with ticagrelor, are the only correlates of post PCI MBG. These findings support the earliest possible loading with ticagrelor prior to primary PCI.

Keywords

ST-elevation myocardial infarction platelet reactivity myocardial reperfusion ticagrelor

Get full access to this article

View all access options for this article.

References

Ruggeri

ZM.

Platelets in atherothrombosis. Nat Med 2002; 8: 1227–1234.

Althoff

Fischer

Langer

et al. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res 2010; 125: e190–e196.

Geisler

Kapp

Gohring-Frischholz

et al. Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 2008; 94: 743–747.

Price

Angiolillo

Teirstein

et al. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. Circulation 2011; 124: 1132–1137.

Stone

Witzenbichler

Weisz

et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013; 382: 614–623.

Chung

Kirtane

Zhang

et al. Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. Am Heart J 2018; 205: 77–86.

Gori

Grifoni

Valenti

et al. High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. Eur J Intern Med 2016; 30: 49–54.

Ibanez

James

Agewall

et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119–177.

Beygui

Castren

Brunetti

et al. Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC. Eur Heart J Acute Cardiovasc Care. DOI: 10.1177/2048872615604119. Epub ahead of print 11 September 2015.

10.

Morishima

Sone

Okumura

et al. Angiographic no-reflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202–1209.

11.

van ’

Hof

Liem

Suryapranata

et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302–2306.

12.

Luo

Liu

et al. Combination of P2Y12 reaction unit and percentage of platelet inhibition assessed by VerifyNow P2Y12 assay is a useful predictor of long-term clinical outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Thromb Res 2016; 139: 114–120.

13.

Tantry

Bonello

Aradi

et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013; 62: 2261–2273.

14.

Gibson

de Lemos

Murphy

et al. Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: A TIMI 14 substudy. Circulation 2001; 103: 2550–2554.

15.

Gibson

Schomig

Coronary and myocardial angiography: Angiographic assessment of both epicardial and myocardial perfusion. Circulation 2004; 109: 3096–3105.

16.

Montalescot

van’t Hof

Lapostolle

et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014; 371: 1016–1027.

17.

Vavuranakis

Vrachatis

Papaioannou

et al. Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. Impact on intracoronary thrombus burden and myocardial perfusion. Circulation J 2011; 75: 2105–2112.

18.

Ferreiro

Homs

Berdejo

et al. Clopidogrel pretreatment in primary percutaneous coronary intervention: Prevalence of high on-treatment platelet reactivity and impact on preprocedural patency of the infarct-related artery. Thromb Haemost 2013; 110: 110–117.

19.

Capranzano

Capodanno

Bucciarelli-Ducci

et al. Impact of residual platelet reactivity on reperfusion in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Eur Heart J Acute Cardiovasc Care 2016; 5: 475–486.

20.

O’Donoghue

Wiviott

SD.

Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all?

Circulation 2006; 114: e600–e606.

21.

Huczek

Filipiak

Kochman

et al. Baseline platelet reactivity in acute myocardial infarction treated with primary angioplasty – influence on myocardial reperfusion, left ventricular performance, and clinical events. Am Heart J 2007; 154: 62–70.

22.

Poulsen

Jorgensen

Korsholm

et al. Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction. Thromb Res 2007; 119: 555–562.

23.

Gurbel

Bliden

DiChiara

et al. Evaluation of dose-related effects of aspirin on platelet function: Results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007; 115: 3156–3164.

24.

Santos

Madrid

Moscardo

et al. The administration of a loading dose of aspirin to patients presenting with acute myocardial infarction while receiving chronic aspirin treatment reduces thromboxane A2-dependent platelet reactivity. Platelets 2014; 25: 268–273.

25.

Grove

Hvas

Johnsen

et al. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost 2010; 103: 1245–1253.

26.

Godschalk

Byrne

Adriaenssens

et al. Observational study of platelet reactivity in patients presenting with ST-segment elevation myocardial infarction due to coronary stent thrombosis undergoing primary percutaneous coronary intervention: Results from the European PREvention of Stent Thrombosis by an interdisciplinary global European effort registry. JACC Cardiovasc Interv 2017; 10: 2548–2556.

27.

Fefer

Beigel

Varon

et al. Bimodal response to aspirin loading in acute ST-elevation myocardial infarction. Platelets 2013; 24: 435–440.

28.

Chen

Lee

et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 2004; 43: 1122–1126.

29.

Mayer

Bernlochner

Braun

et al. Aspirin treatment and outcomes after percutaneous coronary intervention: Results of the ISAR-ASPI registry. J Am Coll Cardiol 2014; 64: 863–871.

30.

Kirtane

Vafai

Murphy

et al. Angiographically evident thrombus following fibrinolytic therapy is associated with impaired myocardial perfusion in STEMI: A CLARITY-TIMI 28 substudy. Eur Heart J 2006; 27: 2040–2045.

31.

Storey

Angiolillo

Patil

et al. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol 2010; 56: 1456–1462.

32.

Parodi

Valenti

Bellandi

et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601–1606.

33.

Gawaz

Neumann

Ott

et al. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996; 93: 229–237.

34.

Parodi

Xanthopoulou

Bellandi

et al. Ticagrelor crushed tablets administration in STEMI patients: The MOJITO study. J Am Coll Cardiol 2015; 65: 511–512.